Drug intelligence / Profile preview

BX011 + BX211

Development stage: Unknown
Lead developer: BiomX, Inc.
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Intravenous, Topical

Overview

BX011 and BX211 are phage-based therapies developed by BiomX targeting *Staphylococcus aureus* infections. BX211 is a phage product that has completed a Phase 2 trial for diabetic foot osteomyelitis (DFO), demonstrating safety and efficacy in reducing ulcer size and depth. BX011 is a next-generation, fixed multi-phage cocktail designed to target *S. aureus* in diabetic foot infections (DFI), incorporating phages previously validated in the BX211 program. These therapies utilize the natural lytic cycle of bacteriophages to specifically infect and destroy pathogenic bacteria without affecting the host's commensal flora. The development has been supported by non-dilutive funding from the U.S. Department of Defense and partnerships with major pharmaceutical companies like Janssen and Boehringer Ingelheim.

Beyond the preview

Go deeper on BX011 + BX211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BX011 + BX211.

Explore the full profile